Journal Article
. 2015 Apr;151(1).
doi: 10.1007/s10549-015-3366-7.

Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy

Lindsey Enewold 1 Ann M Geiger  JoAnne Zujewski  Linda C Harlan  
  • PMID: 25859924
  •     15 citations


The 21-gene recurrence score (RS) assay (Oncotype DX™) predicts the likelihood of breast cancer recurrence and chemotherapy responsiveness. The aims of this study were to describe temporal trends in assay usage, to investigate factors associated with the receipt of the assay and to determine how the assay is associated with treatment decisions. Random samples of stage I-II female breast cancer patients diagnosed in 2004, 2005 and 2010 as reported to the National Cancer Institute's Surveillance Epidemiology and End Results program were included. Among women diagnosed in 2010 with estrogen receptor positive (ER+), lymph node-negative (LN-) tumors, factors associated with receipt of the assay were identified and the likelihood of chemotherapy by RS was estimated. Assay usage increased over time (ER+/LN-:8.0-27.0 %, p < 0.01; ER+/LN+: 2.0-15.7 %, p = 0.09; ER-: 0.2-1.7 %, p < 0.01) from 2005 to 2010. Receipt of the assay was associated with younger age, lower area income and tumor characteristics. Among women in the low (RS < 18) and high risk (RS > 30) categories, 3.3 and 95.9 % received chemotherapy, respectively. Within the intermediate risk group the receipt of chemotherapy varied: 12.8 % (RS: 18-19), 35.0 % (RS: 20-23) and 84.0 % (RS: 24-30). During the study years, assay usage increased among women for whom the assay is and is not guideline recommended. Factors such as insurance and race/ethnicity do not appear to be associated with the receipt of the assay. The RS, as determined broadly via three categories and within the intermediate risk group, does appear to influence chemotherapy decisions.

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.
Chalanda N Evans, Noel T Brewer, +6 authors, Suzanne C O'Neill.
Breast Cancer Res Treat, 2016 Apr 10; 156(3). PMID: 27059031    Free PMC article.
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Amila Orucevic, Robert E Heidel, John L Bell.
Breast Cancer Res Treat, 2016 May 22; 157(3). PMID: 27206678    Free PMC article.
Breast cancer multigene testing trends and impact on chemotherapy use.
G Thomas Ray, Jeanne Mandelblatt, +4 authors, Tracy A Lieu.
Am J Manag Care, 2016 Jun 09; 22(5). PMID: 27266581    Free PMC article.
Progress in the clinical detection of heterogeneity in breast cancer.
Jun-Long Song, Chuang Chen, Jing-Ping Yuan, Sheng-Rong Sun.
Cancer Med, 2016 Oct 25; 5(12). PMID: 27774765    Free PMC article.
Oncologist and organizational factors associated with variation in breast cancer multigene testing.
Tracy A Lieu, G Thomas Ray, +8 authors, Jeanne S Mandelblatt.
Breast Cancer Res Treat, 2017 Feb 23; 163(1). PMID: 28224383    Free PMC article.
21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?
Bridget A Oppong, Surupa Sen Gupta, +6 authors, Shawna C Willey.
Gland Surg, 2018 Jan 06; 6(6). PMID: 29302485    Free PMC article.
Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer.
Jae-Myung Kim, Jai Min Ryu, +6 authors, Jeong Eon Lee.
J Breast Cancer, 2018 Jul 03; 21(2). PMID: 29963119    Free PMC article.
Oncotype testing in patients undergoing intraoperative radiation for breast cancer.
Kelsey E Larson, Stephanie A Valente, +7 authors, Stephen R Grobmyer.
Mol Clin Oncol, 2018 Oct 23; 9(5). PMID: 30345048    Free PMC article.
Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes.
Alina M Mateo, Anna M Mazor, +7 authors, Richard J Bleicher.
Clin Breast Cancer, 2019 Mar 16; 19(4). PMID: 30871966    Free PMC article.
Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system.
Esther C Yoon, Christopher Schwartz, +3 authors, Farbod Darvishian.
Breast J, 2019 Jun 15; 25(5). PMID: 31197914    Free PMC article.
Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes.
Jinani Jayasekera, Susan T Vadaparampil, +8 authors, Suzanne C O'Neill.
JCO Oncol Pract, 2020 May 29; 16(10). PMID: 32463763    Free PMC article.
Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer.
Yunan Han, Zhi-Feng Miao, +3 authors, Ying Liu.
Breast Cancer Res Treat, 2020 Sep 16; 184(3). PMID: 32929567    Free PMC article.
Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar.
Suzanne C O'Neill, Susan T Vadaparampil, +9 authors, Susan Eggly.
Patient Educ Couns, 2020 Sep 10; 104(2). PMID: 32900604    Free PMC article.
A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
J Transl Med, 2021 Feb 18; 19(1). PMID: 33593381    Free PMC article.